# Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Source: https://onco.cc/trials/nct07357519/  
OnCo record `nct07357519` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LNTH2403 Phase 1 dose in osteosarcoma, run by Lantheus Medical Imaging, now recruiting.

## Summary

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) is a phase 1/2 interventional study registered as NCT07357519 by Lantheus Medical Imaging, with 55 participants planned, started 2026-02-03 and due to reach its primary completion in 2027-08. Interventions recorded: LNTH2403 Phase 1 dose and Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D)..

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07357519
- Phase: 1/2
- Setting: A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, -Radiation Dosimetry, and Preliminary Anti-Neoplastic Activity of LNTH-2403, a LRRC15-targeted 177Lutetium-labeled Monoclonal Antibody, in Participants With Relapsed / Refractory Osteosarcoma
- Sponsor: Lantheus Medical Imaging
- Enrolled: 55

## Sources

- ClinicalTrials.gov NCT07357519: https://clinicaltrials.gov/study/NCT07357519

## Connected records

- cancers: [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07357519.json